Tumor-associated macrophages, epidermal growth factor receptor correlated with the triple negative phenotype in endometrial endometrioid adenocarcinoma

Pathology Research and Practice

Volumn 208, Issue 12, 2012, Pages 730-735

  Jiang, Xue feng ^a   Tang, Qiong lan ^b   Shen, Xi ming ^b   Li, Hai gang ^b   Chen, Lun hua ^c   Wang, Xiao yu ^a   Luo, Xin ^a   Lin, Zhong qiu ^b   Jiang, Guang yu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF JINAN UNIVERSITY   (China)

^b SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c AFFILIATED HOSPITAL OF NORTH SICHUAN MEDICAL COLLEGE   (China)

Author keywords

Endometrial endometrioid adenocarcinoma; Epidermal growth factor receptor; Human epidermal growth factor receptor 2; Tumor associated macrophages

Indexed keywords

CD68 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ADVANCED CANCER; ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA; ENDOMETRIOID CARCINOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PELVIS LYMPH NODE; PHENOTYPE; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; UTERUS TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CARCINOMA, ENDOMETRIOID; COHORT STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MACROPHAGES; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84870290928     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2012.09.011     Document Type: Article

References (23)

1. Kothari R., Morrison C., Richardson D., Seward S., O'Malley D., Copeland L., Fowler J., Cohn D.E. The prognostic significance of the triple negative phenotype in endometrial cancer. Gynecol. Oncol. 2010, 118:172-175.
2. De Visser K.E., Coussens L.M. The inflammatory tumor microenvironment and its impact on cancer development. Contrib. Microbiol. 2006, 13:118-137.
3. Mantovani A. Cancer: inflammation by remote control. Nature 2005, 435:752-753.
4. Ohno S., Ohno Y., Suzuki N. Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res. 2004, 45:3335-3342.
5. Hashimoto I., Kodama J., Seki N. Macrophage infiltration and angiogenesis in endometrial cancer. Anticancer Res. 2000, 20:4853-4856.
6. Espinosa I., José Carnicer M., Catasus L., Canet B., D'angelo E., Zannoni G.F., Prat J. Myometrial invasion and lymph node metastasis in endometrioid carcinomas: tumor-associated macrophages, microvessel density, and HIF1A have a crucial role. Am. J. Surg. Pathol. 2010, 34:1708-1714.
7. Soeda S., Nakamura N., Ozeki T., Nishiyama H., Hojo H., Yamada H., Abe M., Sato A. Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma. Gynecol. Oncol. 2008, 109:122-128.
8. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int. J. Gynaecol. Obstet. 2009, 105:109.
9. Konecny G.E., Santos L., Winterhoff B., Hatmal M., Keeney G.L., Mariani A., Jones M., Neuper C., Thomas B., Muderspach L., Riehle D., Wang H.J., Dowdy S., Podratz K.C., Press M.F. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br. J. Cancer 2009, 100:89-95.
10. M.J. Horner, L.A.G. Ries, M. Krapcho, et al., SEER Cancer Statistics Review, 1975-2006, National Cancer Institute, Bethesda, MD, , based on November 2008 SEER data submission, posted to the SEER website, 2009. http://seer.cancer.gov/csr/1975_2006/.
11. Tang Q., Jiang X., Li H., Lin Z., Zhou X., Luo X., Liu L., Chen G. Expression and prognostic value of WISP-1 in patients with endometrial endometrioid adenocarcinoma. J. Obstet. Gynaecol. Res. 2011, 37:606-612.
12. Modugno F., Ness R.B., Chen C., Weiss N.S. Inflammation and endometrial cancer: a hypothesis. Cancer Epidemiol. Biomarkers Prev. 2005, 14:2480-2487.
13. Buechler C., Ritter M., Orso E., Langmann T., Klucken J., Schmitz G. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and anti-inflammatory stimuli. J. Leukoc. Biol. 2000, 67:97-103.
14. Medrek C., Pontén F., Jirström K., Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 2012, 12:306.
15. Condeelis J., Segall J.E. Intravital imaging of cell movement in tumours. Nat. Rev. Cancer 2003, 3:921-930.
16. Leek R.D., Hunt N.C., Landers R.J., Lewis C.E., Royds J.A., Harris A.L. Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J. Pathol. 2000, 190:430-436.
17. Viale G., Rotmensz N., Maisonneuve P. Invasive ductal carcinoma of the breast with the " triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res. Treat. 2009, 116:317-328.
18. Corkery B., Crown J., Clynes M., O'Donovan N. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann. Oncol. 2009, 20:862-867.
19. Inoue S., Patil R., Portilla-Arias J., Ding H., Konda B., Espinoza A., Mongayt D., Markman J.L., Elramsisy A., Phillips H.W., Black K.L., Holler E., Ljubimova J.Y. Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer. PLoS ONE 2012, 7:e31070.
20. Ai Z., Wang J., Wang Y., Lu L., Tong J., Teng Y. Overexpressed epidermal growth factor receptor (EGFR)-induced progestin insensitivity in human endometrial carcinoma cells by the EGFR/mitogen-activated protein kinase signaling pathway. Cancer 2010, 116:3603-3613.
21. Purohit A., Newman S.P., Reed M.J. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res. 2002, 4:65-69.
22. Van der Horst P.H., Wang Y., Vandenput I., Kühne L.C., Ewing P.C., van Ijcken W.F., van der Zee M., Amant F., Burger C.W., Blok L.J. Progesterone inhibits epithelial-to-mesenchymal transition in endometrial cancer. PLoS ONE 2012, 7:e30840.
23. Chaffer C.L., Weinberg R.A. A perspective on cancer cell metastasis. Science 2011, 331:1559-1564.